BioSpace News Archive

Business

uniQure Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress

uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the second quarter of 2023 and highlighted recent progress across its business.

August 1, 2023
·
15 min read
Business

TG Therapeutics and Neuraxpharm Announce Ex-US Commercialization Agreement for BRIUMVI® (ublituximab-xiiy)

TG Therapeutics, Inc. (NASDAQ: TGTX) (TG) and Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, today announced an agreement for the ex-US commercialization of BRIUMVI® (ublituximab).

August 1, 2023
·
17 min read
Business

Clearside Biomedical to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Monday, August 14, 2023

Clearside Biomedical, Inc. announced today that its second quarter 2023 financial results will be reported on Monday, August 14, 2023 after the close of the financial markets.

August 1, 2023
·
1 min read
Deals

Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital

Revolution Medicines, Inc. and EQRx, Inc. announced a definitive agreement through which Revolution Medicines plans to acquire EQRx in an all-stock transaction intended to add more than $1 billion in net cash to Revolution Medicines’ balance sheet.

August 1, 2023
·
21 min read
Chinese Patent Granted for A*STAR Spinoff, CytoMed Therapeutics’ Licensed Allogeneic CAR-Gamma Delta T Cell Technology

CytoMed Therapeutics Limited announced that the chimeric antigen receptor gamma delta T cell technology, which is exclusively licensed from the Agency for Science, Technology and Research, has been granted a patent by the China National Intellectual Property Administration.

August 1, 2023
·
6 min read
Bio NC

RedHill Biopharma Announces Talicia Approved in the United Arab Emirates and First Commercial Order Outside the U.S.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that its partner, Gaelan Medical LLC, a wholly owned subsidiary of the Ghassan Aboud Group, has received marketing approval from the United Arab Emirates Ministry of Health for Talicia.

August 1, 2023
·
15 min read
Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticals

CASI Pharmaceuticals, Inc. announced the execution of an Assignment Agreement with Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. for the commercialization of FOLOTYN® in the People’s Republic of China.

August 1, 2023
·
7 min read
Business

Neurocrine Biosciences Reports Second Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the second quarter ended June 30, 2023 and raised net sales guidance for INGREZZA in 2023.

August 1, 2023
·
14 min read
C4X Discovery Holdings PLC Announces Divestment of Orexin-1 to Indivior for £15.95m

C4X Discovery Holdings plc, a pioneering Drug Discovery company, announces the execution of an asset purchase agreement for Indivior PLC to acquire the proprietary rights to C4XD’s oral Orexin-1 receptor antagonist, C4X_3256 for substance use disorder, for £15.95 million.

August 1, 2023
·
4 min read
Biotech Bay

First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas

Boehringer Ingelheim, a leading research-driven biopharmaceutical company, continues to advance its pipeline in both Human Pharma and Animal Health expanding across its key therapy areas.

August 1, 2023
·
4 min read